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The treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids or anti-oxidants is still 
under debate and the identification of sub-groups of COPD patients who may benefit from either anti-inflammatory 
or anti-oxidant treatment is needed. 
We re-analysed data from an earlier study of inhaled beclomethasone therapy in COPD (n=28) and asthma 
(n=28) patients in order to determine patient characteristics that predict a favourable inhaled steroid treatment 
effect. 
A higher bronchodilatory response, a faster decline of FEV, prior to the treatment period and a lower Tiffeneau 
index were significantly related to more beneficial treatment effects. Increased smoking tended to be related to less 
steroid treatment benefits, though it was not statistically significant. In this paper these findings are presented in light 
of the available literature on anti-inflammatory and anti-oxidant COPD treatment. 
On this basis the hypothesis is presented that anti-oxidant treatment might be relatively more effective among 
those COPD patients who respond less well to inhaled steroids (low reversibility and heavy smoking). 
RESPIR. MED. (1998) 92, 1259-1264 
Introduction 
We discuss here possible agents that may alter the decline of 
lung function in chronic obstructive pulmonary disease 
(COPD) patients. At the recently held annual congress of 
the European Respiratory Society, the results of a large 
multi-centre trial into COPD (the EUROSCOP study 
were presented (1). Within a large group of heavy smokers 
with pulmonary obstruction and a very low reversibility, a 
3-year daily dosage of 8OOpg budesonide was compared to 
placebo and appeared to be only minorly beneficial to the 
course of the post-bronchodilator FEV,. Furthermore, at 
the congress the present state of several other, large, 
long-term studies on the role of inhalation corticosteroids 
(ICS) in COPD were presented (ISOLDE, Copenhagen 
City Lung Study, Lung Health Study II). These studies 
differ from each other in severity of the COPD subjects and 
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pharmacological agents used. In addition to these ICS trials 
a recently initiated large trial among COPD patients was 
presented in which the efficacy of the anti-oxidant 
N-acetylcystein will be studied (BRONCUS). All these 
trials aim to study the effect of these drugs on the decline of 
the postbronchodilator FEV,. 
It is likely that inflammatory mechanisms as well as 
oxidative mechanisms play an important role in the devel- 
opment and progression of COPD (2,3). Morphological 
changes in chronic bronchitis are characterized by mucous 
gland hypertrophy and hyperplasia, goblet cell metaplasia, 
smooth muscle hypertrophy and loss of ciliary function, 
associated with mononuclear inflammatory cell infiltration 
(2,4). Mucus hypersecretion and reduction in mucociliary 
clearance may cause mucus retention in the airways facili- 
tating viral or bacterial superinfection (5). The presence of 
bacteria or viruses is thought to cause an alteration of host 
defences with accumulation of neutrophils, macrophages 
and T lymphocytes in the bronchial mucosa (6). Moreover, 
the process may become self-perpetuating with the 
release of cytokines and substances with proteolytic action. 
Activated neutrophils, which are increased in sputum dur- 
ing acute exacerbations, can cause lung tissue damage 
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TABLE 1. Relationship between clinical characteristics and change in FEV, during 2-year 8OOpg 
beclomethasone treatment daily as assessed by ANCOVA in 28 patients with asthma and 28 patients 
with COPD [based on a re-analysis of an earlier published study (28)]. The estimate of FEV, is given 
in 1O-3 1 (SEM in parentheses.) Two-tailed P-values ~0.05 were considered statistically significant 
COPD Asthma 
Variable Estimate P-value Estimate P-value 
Pack-years - 4.6 (5.1) 0.38 - 3.2 (5.0) 0.54 
Smoking ( * ) - 319 (176) 0.086 - 136 (142) 0.35 
Allergy ( 5 ) - 81 (430) 0.85 220 (131) 0.11 
FEV,/VC (%) 15.6 (6.0) 0.018 - 6.6 (5.2) 0.21 
Slope-FEV, (10 - 3 1 yr - ‘) 1.7 (0.3) 0~0001 1.8 (0.5) 0.001 
BDR-FEV, (1) 0.95 (0.11) 0.000 1 0.76 (0.21) 0.002 
210gPc,, - 3.9 (17.7) 0.83 - 45.6 (20.9) 0.066 
DI-PEFR (%) 6.0 (12.9) 0.65 13.11 (6.4) 0.052 
CV-PEFR (%) 27.7 (29.4) 0.36 11.7 (15.1) 0.45 
Slope-FEV,, Annual decline in FEV, in 2 years before steroid treatment; BDR-FEV,, broncho- 
dilating response in FEV, 60 min after ipratropium 80 pug and salbutamol 400 pug; CV-PEFR, 
week-to-week coefficient of variation of the PEFR; DI-PEFR, diurnal PEFR index (absolute 
difference between evening and morning value divided by the highest value; FEV,, forced expira- 
tory volume in 1 s; PC,,, provoking concentration of histamine producing a 20% fall in FEV,; 
SEM, standard error of the mean. 
variables assessed before the start of steroid treatment were 
related to the changes in FEV, during the 2-year steroid 
treatment period by means of analysis of covariance 
(ANCOVA). By this procedure it can be estimated which 
variable predicts best the decline in FEV, during steroid 
treatment, in other words, which features determine 
whether patients benefit most from steroid treatment. The 
estimates in the slope (j?) and P-values were calculated and 
are presented in Table 1. The larger the estimate of the 
variable in relation to the SEM (given between brackets) 
the more significantly the variable concerned contributes to 
the FEV, decline. To compare the effects in COPD with 
asthma, the same analysis was done for asthma. Table 1 
shows that in patients with COPD, the improvement in 
FEV, during steroid treatment was larger in patients with 
more airway obstruction (as assessed by the FEVJVC), a 
higher reversibility of this obstruction and a larger decline 
in FEV, before steroid therapy. A non-significant influence 
of current smoking was found (P=O.O86) in COPD: current 
smokers seemed to respond worse on inhaled steroids. 
These observed effects in COPD were only apparent during 
the first 6 months of treatment with the inhaled steroid. In 
asthma we found, besides the larger decline in FEV, before 
steroid therapy and the higher reversibility, tendencies 
towards a better response in patients with a higher 
diurnal peak-flow rate index and a more severe degree of 
bronchial hyperresponsiveness (PzO.052 and PzO.066, 
respectively). 
In discussing the possible predictors of a long-term 
response on ICS, it should be kept in mind that the latter 
studies (28,29), apart from the EUROSCOP study, were 
not primarily set up for this purpose. Our study concerned 
a selective group of patients with COPD: all patients were 
selected on the criterion that they had a decline in lung 
function of more than 80 ml yr- ‘, which make them less 
representative for all patients with COPD (28). As the 
variability in lung function is considerable, most studies 
lack the power for adequate sub-group analysis, which 
withholds their results from generalization into other popu- 
lations. Therefore the results of the clinical trials of ICS in 
COPD (Copenhagen City Lung Study (CCLS), ISOLDE 
study, Lung Health Study II) will be of great importance in 
concluding whether definite sub-groups of COPD may 
benefit specifically from ICS. 
Treatment of COPD with 
N-acetykysteine (NAC) 
Another (much less investigated) possibility in the treat- 
ment of COPD is long-term use of N-acetylcysteine (NAC). 
NAC is the N-acetyl derivative of the aminoacid cysteine, 
which is used as a mucolytic agent and as a precursor of 
glutathione in the treatment of paracetamol overdosing. 
Several controlled clinical trials in patients with chronic 
bronchitis have shown that a 6-month treatment with NAC 
(400-600 mg day - ‘) improved respiratory symptoms, and 
reduced the rate and duration of exacerbations as well as 
the number of sick-days (32-34). 
Originally, the therapeutic efficacy of NAC was ascribed 
to its ability to reduce mucus viscosity and to improve 
mucociliary clearance (35,36). Subsequent studies have 
shown that NAC is an anti-oxidant agent which may 
protect lung tissue against oxidant-induced damage and 
can inhibit the epithelial thickening and secretory cell 
hyperplasia induced by cigarette smoke in rats (37,38). 
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through the release of proteases (elastase), enzymes 
(myeloperoxidase) and generation of oxygen radicals (7). 
Consequently, an infiltration of inflammatory cells causes 
further epithelial damage and wall thickening of small 
airways (2). Small airways disease is presently thought 
to be strongly related to the development of emphysema 
(8,9). 
Increased numbers of reactive oxygen species (ROS) are 
present in the lungs of patients with COPD, as a direct 
result of inhalation (cigarette smoke) or increased produc- 
tion by activated inflammatory cells and activation of the 
xanthine oxidase pathway. These oxidants may inactivate 
a,-AT, one of the main inhibitors of elastase (lo), thus 
contributing to parenchymal damage and loss of lung 
function. Maier et al. showed that bronchoalveolar lavage 
fluid (BALF) of smokers with chronic bronchitis contained 
more oxidized methionine residues of a,-proteinase inhibi- 
tor than healthy subjects (11). Another method to show 
increased numbers of ROS in the lungs is measurement of 
the concentration of hydrogen peroxide (H,O,) in exhaled 
breath. Recently, it was shown that stable COPD patients 
exhaled significantly more H,O, than healthy controls (12). 
In addition, patients with unstable COPD, during exacer- 
bations, had a higher concentration of H,O, in their 
exhaled air, compared to those with stable COPD, indicat- 
ing increased oxidative stress (12). Furthermore, a reduc- 
tion in anti-oxidative capacity in plasma was found during 
acute exacerbations of COPD (13). 
Both the inflammatory and the oxidative mechanisms 
may provide additional treatment possibilities. A primary 
goal in the treatment of COPD is to reverse or attenuate the 
accelerated loss of lung function in the long term. For now 
the treatment spectrum includes avoidance of initiating and 
aggravating triggers such as tobacco smoke and specific 
work-related irritants. Other non-pharmacological treat- 
ment modalities include nutrition, immunization against 
influenza, supplemental oxygen, breathing exercises and 
pulmonary rehabilitation. Optimal bronchodilatation 
should be sought using inhaled anticholinergics and/or 
P,-sympaticomimetic drugs. While most COPD patients 
still experience accelerated loss of ventilatory capacity, 
the identification of sub-groups of COPD patients that 
may benefit from additional anti-inflammatory or anti- 
oxidant treatment becomes pressing. In this paper we 
intend to contribute to this discussion. 
Treatment of COPD with inhaled 
corticosteroids (ICS) 
As ICS are very efficacious in asthma, many patients 
with COPD are also treated with them. The type of 
inflammation in COPD, however, differs from asthma and 
it has become apparent that the long-term efficacy of ICS in 
COPD is less obvious compared to asthma (14-16). 
Most short-term studies in COPD showed that ICS have 
some (small) beneficial effects on lung function (17-23) but 
others did not show an improvement (24-26). None of these 
studies showed any effect on bronchial hyperresponsiveness 
and had only a small effect on symptoms (24,25). 
In general, long-term studies showed a similar tendency 
(27-29): small improvement in lung function, no change in 
bronchial hyperresponsiveness, decrease of symptoms to a 
small extent (27,28) and a small reduction in the number of 
exacerbations (2829). The results of the EUROSCOP 
study, the largest long-term study, concur with this (1). 
Budesonide inhaled for 3 years at 800 ,ug day - ‘, was shown 
to have only a small beneficial effect on lung function 
among heavy smokers with mild COPD and a low revers- 
ibility (ERS, Berlin and Geneva). However, the improve- 
ment of FEV, was mainly due to the first 3-6 months of 
treatment. After this initial benefit, the FEV, level paral- 
leled the same linear decline as in the placebo group. This 
pattern an initial benefit of ICS treatment on the FEV, level 
occurring in the first 3-6 months, followed by a parallel 
decline to the placebo group was observed earlier in COPD 
and suggests that a major part of the chronic airway 
obstruction in COPD cannot be influenced by long-term 
ICS treatment (28). In this regard, identification of clinical 
characteristics which may predict a favourable response of 
COPD patients to ICS with regard to the long-term course 
of FEV, seems sensible and (urgently) needed (30,31). 
In a mixed group of asthma and COPD patients (n=91) 
treated with beclomethasone 8OOpg daily for 30 months, 
subjects who did not smoke, had allergy or were less than 
40 years old benefited more from ICS (i.e. improvement in 
lung function) than those who smoked, did not have allergy 
and were over 40 years (29). A further analysis of this study 
showed that bronchodilator response, bronchial hyper- 
responsiveness, total IgE and smoking habits were all 
independent predictors of the treatment response to ICS 
(30). A problem in this study was that no distinction was 
made between asthma and COPD and the inclusion criteria 
(increased hyperresponsiveness and reversibility of obstruc- 
tion) tended to select more asthmatics than patients with 
COPD. So on the basis of this study no firm conclusion can 
be drawn about predictors of a long-term response on 
inhaled steroids in COPD. 
The EUROSCOP study identified less heavy smoking 
history (less pack-years) as a determinant of a positive 
response to ICS. Furthermore, it was observed that in 
addition to the initial effect in the first 3-6 months, the 
benefits of ICS for less heavy smokers increased slowly 
during the remaining years of the study. A non-significant 
trend was observed for more treatment effect of ICS among 
subjects with more reversibility. However, as the subjects of 
this study were selected on the basis of a very low revers- 
ibility, this design may not allow a definite evaluation of the 
influence of reversibility. Surprisingly phadiatop status and 
age were not correlated with the response to ICS in this 
population. 
We have analysed the data of our study (28) in order to 
investigate which sub-groups of patients with COPD 
responded most to inhaled corticosteroids in this study. 
This study concerned a 4-year study in which 28 patients 
with asthma and 28 with COPD used no inhaled steroids 
for 2 years followed by 2 years of using 800,ug beclo- 
methasone dipropionate daily. Our hypothesis was that 
COPD patients with more asthmatic features would benefit 
most from treatment with inhaled steroids. Therefore, the 
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inhaled steroids 
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FIG. 1. Hypothetical graph of the relative efficacy of anti-oxidant (N-acetylcysteine=NAC) and anti-inflammatory 
(inhalation corticosteroids=ICS) treatment in COPD on the basis of patient characteristics. 
Moreover, NAC penetrates into cells, where it is 
deacetylated to L-cysteine, thus supporting the biosynthesis 
of glutathione, which is one of the most important anti- 
oxidant systems in the cell. Indeed, the maintenance of 
intracellular glutathione stores plays a key role in the cell 
protection (39). In an in vitro study NAC has been shown to 
inhibit neutrophil and monocyte chemotaxis and oxidative 
burst responses (40). In smokers, NAC (600 mg day - ’ 
orally) decreases lysozyme and lactoferrin concentrations 
and reduces the activation and number of neutrophils 
and alveolar macrophages, recovered from BAL fluid 
(4143). NAC has also been found to protect a,-AT against 
oxidative inactivation (10). The decrease in the incidence of 
exacerbations may be explained by a decrease in bacterial 
colonization by Streptococcuspneumoniae and Haemophilus 
influenzae in the airways of chronic bronchitis during 
treatment with NAC (44). 
An open study in patients with mild-to-moderate COPD 
suggested that NAC could reduce the yearly decline in 
lung function (45). This effect was most pronounced in 
patients who were older than 50 years of age. A direct link 
between these clinical effects (i.e. reduction in the number 
of exacerbations and reduction in the decline of lung 
function) and its anti-oxidative capacity as mechanism 
of action, however, has not been established thus far. 
Long-term prospective studies investigating this are just 
beginning. 
Hypothesis 
These observations have brought us to the hypothesis that 
the anti-oxidant effect of NAC might be most efficacious in 
COPD patients who are heavy smokers with a largely 
irreversible airflow obstruction. In other words, NAC 
might be most efficacious in those subjects who are less 
responsive (or even resistant) to ICS (see Fig. 1). This 
hypothesis could be tested in a long-term placebo con- 
trolled randomized trial with ICS and NAC in COPD 
patients with a wide variety of possible determinants (such 
as smoking behaviour, reversibility of obstruction, age, etc). 
The Dutch Health Insurance Council and the Dutch 
Asthma Foundation have recently decided to support such 
a study (the Co-opt study). If this hypothesis is true it will 
have important consequences for the daily treatment of 
COPD. At the moment no serious alternatives are available 
for steroid therapy, although we know that the effects of 
these drugs in COPD are very limited. 
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